KRYSTEXXA

This brand name is authorized in Estonia, Lithuania, United States

Active ingredients

The drug KRYSTEXXA contains one active pharmaceutical ingredient (API):

1 Pegloticase UNII R581OT55EA - PEGLOTICASE

Pegloticase is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water soluble purine metabolite; it is readily eliminated, primarily by renal excretion. Read about Pegloticase

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KRYSTEXXA Solution for infusion	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M04AX02		M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AX Other antigout preparations
Discover more medicines within M04AX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1605002
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069217
Country: US	FDA, National Drug Code	Identifier(s): 75987-080